Confidence interval criteria for assessment of dose proportionality.
| Ingredient | Quantity Per Tablet | Function | Source |
|---|---|---|---|
| Tadalafil | 20 mg | Main active component | Lilly Laboratories |
| Croscarmellose | 1.5 mg | Disintegrant | Pharmaceutical Grade |
| Microcrystalline Cellulose | 2 mg | Filling agent | Pharmaceutical Supplier |
| Magnesium Stearate | 0.2 mg | Lubricant | Chemical Manufacturer |
23.Little RC, Milliken GA, Stroup WW, Wolfinger RD. 26.Lemmer B. Chronopharmacokinetics: implications for drug treatment.
| Standard | Description | Certification | Frequency of Inspection |
|---|---|---|---|
| Good Manufacturing Practice (GMP) | Ensures purity and efficacy of medicines | Yes | Annually |
| ISO 9001 | Quality management system | Yes | Every 2 years |
| Active Ingredient Testing | Confirm potency and purity | Yes | Before batch release |
| Packaging Validation | Ensures safety and integrity of packaging | Yes | Per batch |
29.Troconiz IF, Tillmann C, Staab A, Rapado J, Mackie A, Mitchell M, Patterson B, Forgue ST. Tadalafil population pharmacokinetics in patients with erectile dysfunction.
This value represents an upper limit for blood systemic clearance (CL) since absolute bioavailability (F) cannot exceed 1.0. This calculation, coupled with extensive evidence that the liver is the predominant eliminating organ, characterizes tadalafil as a ‘low hepatic clearance’ drug. Low clearance, coupled with a modest volume of distribution (Vz/F = 63 l) results in a t1/2 that is prolonged relative to other PDE5 inhibitors approved for treatment of erectile dysfunction. For example, sildenafil citrate (Viagra®; Pfizer) has a systemic plasma CL (40.8 l h−1; blood CL not reported) that approaches hepatic plasma flow and a corresponding t1/2 of 4 h [30]. Estimates of t1/2, CL/F, and Vz/F following multiple dose administration were essentially similar to single-dose values, providing strong evidence that tadalafil neither induces nor inhibits its own metabolism.
Funding: Lilly ICOS LLC (Indianapolis, IN and Bothell, WA, USA). We thank Tracy Higgins (Covance, Leeds, West Yorkshire, UK) for contributions to the ISA, Alison Mackie, MS (formerly of the Lilly Research Centre) for scientific support, as well as Diane Stothard PhD, and Elizabeth Agostinelli MA, of Lilly Research Laboratories for editorial assistance. 2.Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC. On-demand IC351 (Cialis®) tadalafil cialis daily enhances erectile function in patients with erectile dysfunction. 5.Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S.
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. The efficacy and safety of tadalafil: an update. Effects of tadalafil on erectile dysfunction in men with diabetes. 8.Rosen RC, Padma-Nathan H, Shabsigh R, Saikali K, Watkins V, Pullman W. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. 30.Nichols DJ, Muirhead GJ, Harness JA.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Cialis Black | 80mg | 120 + 8 Pills | 264.77€ 252.16€ | |
| Cialis Professional | 20mg | 180 + 4 Pills | 423.11€ 402.96€ | |
| Cialis Black | 80mg | 360 + 20 Pills | 639.78€ 609.31€ | |
| Cialis Generic | 10mg | 180 + 8 Pills | 236.88€ 225.60€ | |
| Cialis Super Active | 20mg | 90 + 10 Pills | 314.14€ 299.18€ | |
| Cialis Generic | 2.5mg | 90 + 6 Pills | 112.43€ 107.08€ | |
| Cialis Generic | 2.5mg | 270 + 10 Pills | 199.64€ 190.13€ | |
| Cialis Generic | 10mg | 360 + 10 Pills | 388.49€ 369.99€ | |
| Cialis Professional | 20mg | 20 Pills | 78.33€ 74.60€ | |
| Cialis Generic | 2.5mg | 30 + 4 Pills | 51.95€ 49.48€ | |
| Cialis Soft Tabs | 20mg | 10 Pills | 39.03€ 37.17€ |
Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. [DOI] [PMC free article] [PubMed] [Google Scholar] It works by increasing blood flow to the penis during sexual stimulation, helping to achieve and maintain an erection. It also relaxes the muscles in the prostate and bladder, improving symptoms of BPH. Key features: • Helps achieve and maintain an erection during sexual activity. • Improves urinary symptoms associated with an enlarged prostate.
Accumulation from day 1 to day 10, calculated with either AUC or Cmax data, was approximately 1.6-fold (Table 5). Mean CL/F, Vz/F, and t1/2 values following the last dose were essentially similar to single-dose values, indicating linear pharmacokinetics across time. Exposure was proportional to dose; the 90% CI for the ratio (20 mg/10 mg) of dose-normalized mean AUCτ values was (0.91, 1.30) on day 5 and (0.77, 1.17) on day 10. Corresponding 90% CI intervals for Cmax were (0.82, 1.12) on day 5 and (0.70, 1.01) on day 10. Exposure to the major metabolite (predominately the methylcatechol glucuronide) was also dose-proportional based on 90% CI for dose-normalized mean AUCτ and Cmax values.
Comparison of AUC and Cmax data across days 5 and 10 indicated that steady state was achieved by day 5 (Table 5). Following cessation of dosing, plasma metabolite concentrations declined nearly in parallel with the parent-drug concentrations, suggesting formation rate-limited kinetics of the metabolite. The noncompartmental pharmacokinetic analysis in healthy subjects, taken as a whole, indicates linear pharmacokinetic behaviour with respect to dose and time under the conditions of study. Food had negligible effects on rate and extent of absorption. Hence, tadalafil may be taken without regard to meal timing or fat content of the meal.
Rate and extent of tadalafil absorption in the morning were slightly lower than in the evening. A similar trend has been seen for other lipophilic drugs [26, 27]. Plasma concentrations are essentially proportional to dose, i.e. doubling the dose doubles exposure to tadalafil. Plasma protein binding is constant (94%) across the therapeutic concentration range. • Effects can last up to 36 hours.
• Taken as needed, at least 30 minutes before sexual activity, or once daily for continuous treatment.
Side Effects: • Common side effects include headache, indigestion, back pain, muscle aches, flushing, stuffy or runny nose. • Caution: • Avoid use with nitrates or certain medications due to risk of severe hypotension • Not for individuals with a history of heart problems or severe liver/kidney issues • Seek immediate medical attention for prolonged erections (lasting over 4 hours) or sudden vision loss. Tadalafil is a medicine that is commonly used for the following conditions. Erectile dysfunction, a condition where you have trouble getting or keeping an erection Pulmonary arterial hypertension, a condition where you have high blood pressure in the blood vessels that carry blood from your heart to your lungs Benign prostatic hyperplasia (BPH), a condition where the prostate gland has become enlarged Tadalafil may also be used for other conditions as determined by your healthcare provider. Tadalafil works by blocking the activity of an enzyme called phosphodiesterase 5 (PDE5). This enzyme usually stops some types of muscles from relaxing, including the muscles lining some types of blood vessels.
Washington DC: US Food and Drug Administration, Center for Drug Evaluation and Research; 2002. Statistics with confidence: confidence intervals and statistical guidelines. 21.Gough K, Hutchison M, Keene O. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint Working Party. 22.Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. By blocking PDE5, the muscles will relax and blood flow increases.
Thus, unbound tadalafil concentrations are also dose-proportional. A total plasma concentration of 6 µg l−1 corresponds to the unbound concentration (0.9 nm) needed for half-maximal inhibition of PDE5 in vitro[28]. No serious adverse events occurred in any of the 14 clinical pharmacology studies and the frequency of treatment-emergent adverse events was consistent with findings for efficacy trials with tadalafil [5, 6]. The ISA provided robust summary statistics on basic pharmacokinetics across numerous studies that proved useful for product labelling. The ISA database was large (282 concentration–time profiles for 237 subjects), facilitating detection of small effects of age, gender, BMI and smoking status on some pharmacokinetic parameters (Table 4).
These covariates together explained at most 12% of subject-to-subject variability. Neither age nor smoking status was statistically significant in the population pharmacokinetic analysis of two phase 2 trials in patients with erectile dysfunction (weight was a covariate of distribution volume) [29]. No dose adjustment is warranted based on age or smoking status [11, 12]. An early study (in the ISA database) had indicated that gender had negligible influence on Cmax and only a small effect on AUC; this was confirmed by the ISA. Women were enrolled in some subsequent studies to facilitate recruitment and pharmacokinetic results were summarized across gender.
A first-order absorption rate constant (ka) can be approximated from the median tmax (2 h) and t1/2 (17.5 h) values, recognizing that tmax is merely the time after dosing at which absorption and elimination rates are equal. For a given absorption rate, tmax is prolonged as t1/2 is prolonged, because it takes longer for absorption to decline far enough to match a slower elimination rate. This yields a ka of 2.0 h−1 or a half-time for absorption of 20 min. Detectable tadalafil concentrations are obtained by this time and, in contrast to other PDE5 inhibitors, near maximal (≥80% of Cmax) tadalafil concentrations are present from 1.5 through 6.5 h postdose. Based on the mean oral clearance (CL/F) and a plasma/blood concentration ratio of 1.39 (data on file; Eli Lilly & Co.), CL/F indexed to blood is 3.45 l h−1 (<5% of hepatic blood flow). For erectile dysfunction, it increases blood flow to the penis when aroused. This makes it easier to get and keep an erection. For pulmonary arterial hypertension, tadalafil relaxes the blood vessels in the lungs.
9.Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. 11.Tadalafil (Cialis®) Summary of Product Characteristics. 14.Phillips DL, Smith RL, Patterson BE, Parker N, Mitchell M, Wheeler WJ, Watkins VS, Barbuch RJ. Metabolism and excretion of tadalafil in healthy men after oral administration of 100 mg [14C]-tadalafil.
15.Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo. 16.Patterson B, Bedding AW, Jewel H, Payne CD, Mitchell MI. Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers. 18.Guidance for Industry, Food-Effect Bioavailability and Fed Bioequivalence Studies. This lowers blood pressure and reduces strain on the heart. For benign prostatic hyperplasia, tadalafil relaxes the muscles of the bladder and prostate, making it easier to urinate and reducing symptoms.